Article
Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy - 5 Aug 2026
Sastre-Femenia Miquel Àngel, Gomis-Font Maria Antonia, Fernández-Muñoz Almudena, Salazar-Londoño Daniela, Moya Bartolome, Oliver Antonio
Abstract excerpt
The triple action of the diazabicyclooctane (DBO) zidebactam (antibacterial activity [penicillin-binding protein 2 {PBP2} inhibitor], β-lactam enhancement [synergy with PBP3 inhibitors], and β-lactamase inhibition [classes A and C]) provides a promising approach to overcome Pseudomonas aeruginosa resistance. However, PBP2 mutations (particularly V516M) are associated with resistance. Thus, we characterized the...
Topics
- Pseudomonas aeruginosa
- Azabicyclo Compounds
- Microbial Sensitivity Tests
- Penicillin-Binding Proteins
- Cyclooctanes
- Anti-Bacterial Agents
- Mutation
- Bacterial Proteins
- Bacterial Outer Membrane Proteins
- beta-Lactams
- Membrane Transport Proteins
- beta Lactam Antibiotics